• 1
    Evans TR, Kaye SB, Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids: present role and future potential. Br J Cancer 1999;80: 18.
  • 2
    Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 2000;21: 12719.
  • 3
    Chambon P, Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. The retinoid signaling pathway: molecular and genetic analyses. Semin Cell Biol 1994;5: 11525.
  • 4
    DiSepio D, Sutter M, Johnson AT, Chandraratna RA, Nagpal S. Identification of the AP1-antagonism domain of retinoic acid receptors. Mol Cell Biol Res Commun 1999;1: 713.
  • 5
    Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem 1995;270: 9237.
  • 6
    Salbert G, Fanjul A, Piedrafita FJ, Lu XP, Kim SJ, Tran P, Pfahl M. Retinoic acid receptors and retinoid X receptor-alpha down-regulate the transforming growth factor-beta 1 promoter by antagonizing AP-1 activity. Mol Endocrinol 1993;7: 134756.
  • 7
    Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 1999;59: 148.
  • 8
    Kitareewan S, Spinella MJ, Allopenna J, Reczek PR, Dmitrovsky E. 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARgamma independent pathway. Oncogene 1999;18: 574755.
  • 9
    Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 1999;59: 24938.
  • 10
    Atkin NB, Baker MC. Chromosome 17p loss in carcinoma of the cervix uteri. Cancer Genet Cytogenet 1989;37: 22933.
  • 11
    Biegel JA, Burk CD, Barr FG, Emanuel BS. Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 1992;52: 33915.
  • 12
    Cogen PH, Daneshvar L, Metzger AK, Duyk G, Edwards MS, Sheffield VC. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis. Am J Hum Genet 1992;50: 5849.
  • 13
    Coles C, Thompson AM, Elder PA, Cohen BB, Mackenzie IM, Cranston G, Chetty U, Mackay J, Macdonald M, Nakamura Y, et al., Evidence implicating at least 2 genes on chromosome 17p in breast carcinogenesis. Lancet 1990; 336: 7613.
  • 14
    Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Borresen AL, Cornelisse CJ, Devilee P. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 1994;54: 42006.
  • 15
    Konishi H, Takahashi T, Kozaki K, Yatabe Y, Mitsudomi T, Fujii Y, Sugiura, T, Matsuda, H. Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers. Oncogene 1998;17: 2095100.
  • 16
    Konishi H, Takahashi T, Kozaki K, Yatabe Y, Mitsudomi T, Fujii Y, Sugiura T, Matsuda H, Takahashi T, Takahashi T. Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers. Oncogene 1998;17: 2095100.
  • 17
    Phillips N, Ziegle M, Saha B, Xynos F. Allelic loss on chromosome 17 in human ovarian cancer. Int J Cancer 1993;54: 8591.
  • 18
    Wiper DW, Zanotti KM, Kennedy AW, Belinson JL, Casey G. Analysis of allelic imbalance on chromosome 17p13 in stage I and stage II epithelial ovarian cancers. Gynecol Oncol 1998;71: 7782.
  • 19
    Phillips NJ, Zeigler MR, Deaven LL. A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. Cancer Lett 1996;102: 8590.
  • 20
    Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ, Godwin AK. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 1996;56: 19972002.
  • 21
    Bruening W, Prowse AH, Schultz DC, Holgado-Madruga M, Wong A, Godwin AK. 1999. Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Res 1999;59: 497383.
  • 22
    Liu G, Wu M, Levi G, Ferrari N. Down-regulation of the Diphthamide biosynthesis protein 2-like gene during retinoid-induced differentiation and apoptosis: implications against its tumor-suppressor activity. Int J Cancer 2000; 88; 35662.
  • 23
    Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 1995;55: 21507.
  • 24
    Dunbrack RL. Comparative modeling of CASP3 targets using PSI-BLAST and SCWRL. Proteins (Suppl) 1999; 817.
  • 25
    Salicioni AM, Xi M, Vanderveer LA, Balsara B, Testa JR, Dunbrack RL, Godwin AK. 2000. Identification and structural analysis of human RBM8A and RBM8B: two highly conserved RNA-binding motif proteins that interact with OVCA1, a candidate tumor suppressor. Genomics 2000;69: 5462.
  • 26
    Altschul SF, Koonin EV. Iterated profile searches with PSI-BLAST—a tool for discovery in protein databases. Trends Biochem Sci 1998;23: 4447.
  • 27
    Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res 2000;28: 23542.
  • 28
    Bower MJ, Cohen FE, Dunbrack RL. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J Mol Biol 1997;267: 126882.
  • 29
    Dunbrack RL, Cohen FE. Bayesian statistical analysis of protein side-chain rotamer preferences. Protein Sci 1997;6: 166181.
  • 30
    Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Formelli F, Menard S, Costa A, Veronesi U, Pierotti MA. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993;53: 603641.
  • 31
    Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 1990;79: 44853.
  • 32
    Kim KK, Song HK, Shin DH, Hwang KY, Choe S, Yoo OJ, Suh SW. Crystal structure of carboxylesterase from Pseudomonas fluorescens, an alpha/beta hydrolase with broad substrate specificity. Structure 1997;5: 157184.
  • 33
    Kelley LA, MacCallum RM, Sternberg MJ. Enhanced genome annotation using structural profiles in the program 3D-PSSM. J Mol Biol 2000;299: 499520.
  • 34
    Jones DT, Taylor WR, Thornton JM. A new approach to protein fold recognition. Nature 1992;358: 869.
  • 35
    Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T, Xynos FP, Donis-Keller H. Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res 1996;56: 60611.
  • 36
    De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991;5: 292433.
  • 37
    Li Y, Dawson MI, Agadir A, Lee MO, Jong L, Hobbs PD, Zhang XK. Regulation of RAR beta expression by RAR- and RXR-selective retinoids in human lung cancer cell lines: effect on growth inhibition and apoptosis induction. Int J Cancer 1998;75: 8895.
  • 38
    Tsuchiya E, Tanigami A, Ishikawa Y, Nishida K, Hayashi M, Tokuchi Y, Hashimoto T, Okumura S, Tsuchiya S, Nakagawa K. Three new regions on chromosome 17p13.3 distal to p53 with possible tumor suppressor gene involvement in lung cancer. Jpn J Cancer Res 2000;91: 58996.